Chinese RNA drug developer Ribo has launched a Hong Kong IPO, positioning its lead siRNA candidate for thrombotic diseases as a flagship asset as investors gain rare access to China’s small nucleic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback